A study published Wednesday in Nature Neuroscience sheds light into how amyloid-beta and tau proteins impact brain activity ...

New research suggests that the lessening of amyloid-beta in the brain is behind cognitive decline in Alzheimer's and boosting ...

In the past two years, the U.S. Food and Drug Administration has approved two monoclonal antibody treatments to slow ...

Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...

Amyloid-beta and tau proteins have long been associated with Alzheimer's disease. The pathological buildup of these proteins ...

Much of the brain is made up of a constellation of star-shaped cells called astrocytes, which play vital roles in immunity, ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...

Researchers discover how amyloid-β and tau pathologies interact to drive early neurophysiological changes and cognitive ...

The FDA’s approval of Kisunla demonstrates a positive change in Alzheimer disease management. Offering illness pathology therapy and the option of treatment conclusion after reaching therapeutic goals ...

The scientists looked at two brain scans and found that areas with more amyloid-beta showed increased brain activity, with ...

Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient ...